Cargando…

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice

Smoking is the most common route of administration for cannabis; however, vaping cannabis extracts and synthetic cannabinoids (“fake marijuana”) in electronic cigarette devices has become increasingly popular. Yet, most animal models used to investigate biological mechanisms underlying cannabis use...

Descripción completa

Detalles Bibliográficos
Autores principales: Lefever, Timothy W, Marusich, Julie A, Thomas, Brian F, Barrus, Daniel G, Peiper, Nicholas C, Kevin, Richard C, Wiley, Jenny L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398321/
https://www.ncbi.nlm.nih.gov/pubmed/28469427
http://dx.doi.org/10.1177/1178221817701739
_version_ 1783230442645749760
author Lefever, Timothy W
Marusich, Julie A
Thomas, Brian F
Barrus, Daniel G
Peiper, Nicholas C
Kevin, Richard C
Wiley, Jenny L
author_facet Lefever, Timothy W
Marusich, Julie A
Thomas, Brian F
Barrus, Daniel G
Peiper, Nicholas C
Kevin, Richard C
Wiley, Jenny L
author_sort Lefever, Timothy W
collection PubMed
description Smoking is the most common route of administration for cannabis; however, vaping cannabis extracts and synthetic cannabinoids (“fake marijuana”) in electronic cigarette devices has become increasingly popular. Yet, most animal models used to investigate biological mechanisms underlying cannabis use employ injection as the route of administration. This study evaluated a novel e-cigarette device that delivers aerosolized cannabinoids to mice. The effects of aerosolized and injected synthetic cannabinoids (CP 55,940, AB-CHMINACA, XLR-11, and JWH-018) in mice were compared in a battery of bioassays in which psychoactive cannabinoids produce characteristic effects. The most potent cannabinoids (CP 55,940 and AB-CHMINACA) produced the full cannabinoid profile (ie, hypothermia, hypolocomotion, and analgesia), regardless of the route of administration. In contrast, aerosolized JWH-018 and XLR-11 did not produce the full profile of cannabimimetic effects. Results of time course analysis for hypothermia showed that aerosol exposure to CP 55,940 and AB-CHMINACA produced faster onset of effects and shorter duration of action than injection. The ability to administer cannabinoids to rodents using the most common route of administration among humans provides a method for collecting preclinical data with enhanced translational relevance.
format Online
Article
Text
id pubmed-5398321
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-53983212017-05-03 Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice Lefever, Timothy W Marusich, Julie A Thomas, Brian F Barrus, Daniel G Peiper, Nicholas C Kevin, Richard C Wiley, Jenny L Subst Abuse Original Research Smoking is the most common route of administration for cannabis; however, vaping cannabis extracts and synthetic cannabinoids (“fake marijuana”) in electronic cigarette devices has become increasingly popular. Yet, most animal models used to investigate biological mechanisms underlying cannabis use employ injection as the route of administration. This study evaluated a novel e-cigarette device that delivers aerosolized cannabinoids to mice. The effects of aerosolized and injected synthetic cannabinoids (CP 55,940, AB-CHMINACA, XLR-11, and JWH-018) in mice were compared in a battery of bioassays in which psychoactive cannabinoids produce characteristic effects. The most potent cannabinoids (CP 55,940 and AB-CHMINACA) produced the full cannabinoid profile (ie, hypothermia, hypolocomotion, and analgesia), regardless of the route of administration. In contrast, aerosolized JWH-018 and XLR-11 did not produce the full profile of cannabimimetic effects. Results of time course analysis for hypothermia showed that aerosol exposure to CP 55,940 and AB-CHMINACA produced faster onset of effects and shorter duration of action than injection. The ability to administer cannabinoids to rodents using the most common route of administration among humans provides a method for collecting preclinical data with enhanced translational relevance. SAGE Publications 2017-04-07 /pmc/articles/PMC5398321/ /pubmed/28469427 http://dx.doi.org/10.1177/1178221817701739 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Lefever, Timothy W
Marusich, Julie A
Thomas, Brian F
Barrus, Daniel G
Peiper, Nicholas C
Kevin, Richard C
Wiley, Jenny L
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title_full Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title_fullStr Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title_full_unstemmed Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title_short Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
title_sort vaping synthetic cannabinoids: a novel preclinical model of e-cigarette use in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398321/
https://www.ncbi.nlm.nih.gov/pubmed/28469427
http://dx.doi.org/10.1177/1178221817701739
work_keys_str_mv AT lefevertimothyw vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT marusichjuliea vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT thomasbrianf vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT barrusdanielg vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT peipernicholasc vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT kevinrichardc vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice
AT wileyjennyl vapingsyntheticcannabinoidsanovelpreclinicalmodelofecigaretteuseinmice